Ascletis Pharma director resigns
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Ascletis Pharma Inc. said Wei Fu resigned from the board as a nonexecutive director on Dec. 24 due to other business commitments.
The company said Fu has no disagreement with the board.
China's Ascletis Pharma is an investment holding company that focuses on the development and commercialization of various drugs.